BCAT 📈 BlackRock Capital - Overview
Exchange: NYSE • Country: United States • Currency: USD • Type: Common Stock • ISIN: US09260U1097
BCAT: Stocks, Bonds, Loans, Equities, Debt Securities
Additional Sources for BCAT Stock
News:
Wall Street Journal
Benzinga
Yahoo Finance
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
BCAT Stock Overview
| Market Cap in USD | 1,743m |
| GiC Sub-Industry | Asset Management & Custody Banks |
| IPO / Inception | 2020-09-25 |
BCAT Stock Ratings
| Growth 5y | 21.9% |
| Fundamental | 29.7% |
| Dividend | 93.6% |
| Rel. Strength Industry | -34 |
| Analysts | - |
| Fair Price Momentum | 15.48 USD |
| Fair Price DCF | 43.65 USD |
BCAT Dividends
| Dividend Yield 12m | 15.59% |
| Yield on Cost 5y | 17.81% |
| Annual Growth 5y | 86.75% |
| Payout Consistency | 82.5% |
BCAT Growth Ratios
| Growth Correlation 3m | 18.8% |
| Growth Correlation 12m | 95% |
| Growth Correlation 5y | 3.5% |
| CAGR 5y | 3.17% |
| CAGR/Mean DD 5y | 0.19 |
| Sharpe Ratio 12m | 1.05 |
| Alpha | 1.53 |
| Beta | 0.65 |
| Volatility | 16.99% |
| Current Volume | 676.7k |
| Average Volume 20d | 541.8k |
What is the price of BCAT stocks?
As of January 02, 2025, the stock is trading at USD 15.15 with a total of 676,700 shares traded.
Over the past week, the price has changed by -2.51%, over one month by -5.09%, over three months by -3.34% and over the past year by +19.82%.
As of January 02, 2025, the stock is trading at USD 15.15 with a total of 676,700 shares traded.
Over the past week, the price has changed by -2.51%, over one month by -5.09%, over three months by -3.34% and over the past year by +19.82%.
Is BlackRock Capital a good stock to buy?
Neither. Based on ValueRay Fundamental Analyses, BlackRock Capital is currently (January 2025) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of 29.67 and therefor a neutral outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of BCAT as of January 2025 is 15.48. This means that BCAT is currently overvalued and has a potential downside of 2.18%.
Neither. Based on ValueRay Fundamental Analyses, BlackRock Capital is currently (January 2025) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of 29.67 and therefor a neutral outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of BCAT as of January 2025 is 15.48. This means that BCAT is currently overvalued and has a potential downside of 2.18%.
Is BCAT a buy, sell or hold?
BlackRock Capital has no consensus analysts rating.
BlackRock Capital has no consensus analysts rating.
What are the forecast for BCAT stock price target?
According to ValueRays Forecast Model, BCAT BlackRock Capital will be worth about 17 in January 2026. The stock is currently trading at 15.15. This means that the stock has a potential upside of +12.41%.
According to ValueRays Forecast Model, BCAT BlackRock Capital will be worth about 17 in January 2026. The stock is currently trading at 15.15. This means that the stock has a potential upside of +12.41%.
| Issuer | Forecast | Upside |
|---|---|---|
| Wallstreet Target Price | - | - |
| Analysts Target Price | - | - |
| ValueRay Target Price | 17 | 12.4% |